-
12/14/2022
PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of shares
-
11/30/2022
PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023
-
11/15/2022
PAION AG raises EBITDA forecast for fiscal year 2022
-
04/27/2022
PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA
-
01/07/2022
PAION ASSIGNS CHINESE REMIMAZOLAM PATENTS AND SELLS RELATED FUTURE ROYALTIES FOR EUR 20.5 MILLION TO HUMANWELL HEALTHCARE GROUP